GMP Certification Extended for Cobra Biologics
Cobra Biologics' GMP Compliance Certification has been extended to include QC testing.
Cobra Biologics, an international CMO of biologics andpharmaceuticals, reported that its GMP Compliance Certification has been extended to include QC testing and release of customers’ registered products for in-market supply.
Following an inspection at the company’s center of excellence for mammalian antibody and recombinant protein production in Södertälje, Sweden, the the Läkemedelsverket (Medical Products Agency) has considered that the facility complies with the principles and guidelines of GMP in the Commission Directive 2003/94/EC for Human Medicinal, and Investigational Medicinal, Products.
This improved certification for biological medicinal products includes the manufacturing of active substances by culture of mammalian cells, the storage of both mammalian and microbial cell banks, the release testing of protein for clinical trials, and the QC testing of registered products.
Source: Cobra Biologics
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
